A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
Celgene
M.D. Anderson Cancer Center
Vejle Hospital
Tampere University Hospital
Bristol-Myers Squibb
Austrian Forum Against Cancer
University of Arkansas
WiSP Wissenschaftlicher Service Pharma GmbH
Royal Marsden NHS Foundation Trust
Bellus Health Inc. - a GSK company